(Sharecast News) - Scancell reported progress across its immunotherapy pipeline on Thursday, as it narrowed annual losses and prepared for late-stage development of its lead melanoma treatment.
The AIM-traded biotech said its DNA ImmunoBody candidate iSCIB1+ delivered positive phase two results in the SCOPE trial, showing an 11-month progression-free survival rate...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE